Hematology

Breast cancer incidence has climbed among Asian Americans, while diagnosis rates among other groups have trended downward.

Top news of the week in oncology and cancer drug development.

Oral cancer treatments provide new opportunities for improved overall survival rates, but patients are increasingly responsible for higher out-of-pocket costs as they self-manage their therapy.

Legendary NBA star Kareem-Abdul Jabbar faced his toughest battle after being diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.

Specialty pharmacists are uniquely positioned to help with the treatment of breast cancer.

With the rise of oral oncolytics, the ability to educate patients while providing resources to monitor compliance and adverse-effect management becomes even more critical. 

The final days of the Obama administration witnessed the federal government launch several initiatives seeking to advance the battle against cancer. 

Emerging oncology therapies, often made available to patients through specialty pharmacies, continue to be a key driver and focus of the business.

Suppressing MAFK pathway in tumor cells may slow spread of aggressive breast cancer.

Study provides visualization of different conformations of transporter in motion that may lead to more effective anticancer and antiviral drugs.

Findings may lead to the development of a noninvasive clinical diagnostic test.

Blood test quickly and accurately identifies genetic mutations linked to non-small cell lung cancer.

Key factor helps drive metastases in aggressive cancers.

The Hematology Oncology Pharmacy Association (HOPA) is hosting the HOPA Policy Summit on Drug Waste in the Treatment of Cancer with health care professionals and industry members.

The Hematology Oncology Pharmacy Association (HOPA) is hosting the HOPA Policy Summit on Drug Waste in the Treatment of Cancer with health care professionals and industry members.

Top news of the week in oncology and cancer drug development.

Methotrexate oral solution (Xatmep) indicated to treat pediatric patients.

Midostaurin demonstrated a statistically significant improvement in overall survival among AML patients.

Midostaurin (Rydapt) approved to treat acute FLT3 mutation positive acute myeloid leukemia.

Stivarga expanded to include the treatment of hepatocellular carcinoma in patients previously treated with sorafenib.

Stivarga is the first FDA-approved treatment for hepatocellular carcinoma in almost a decade.

Top news of the week in oncology and cancer drug development.

Findings could help improve treatment efficacy for patients with ALL.

Multiple myeloma survivor seeks to empower patients by illustrating the value of human life.

Protein determines whether breast cancer cells become resistant to tamoxifen.